Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Toshio Kokuryo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7176-7581; OpenAlex author ID A5026188526, A5083247930. Sources: OpenAlex.

Their work

Papers
12 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 12

  1. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Co-author DOI 10.1093/bjs/znaf049↗
  2. FAM111B Suppression Enhances Sensitivity to Gemcitabine in Pancreatic Cancer Through Intracellular pH Regulation. Co-author DOI 10.1111/cas.70212↗
  3. Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer. First author DOI 10.1002/cam4.7395↗
  4. Antitumor Effects of Deep Ultraviolet Irradiation for Pancreatic Cancer. First author DOI 10.21873/anticanres.16198↗
  5. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer. First author DOI 10.21873/anticanres.16245↗
  6. Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.07.188↗
  7. The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer. First author DOI 10.21873/anticanres.11352↗
  8. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.12993↗
  9. α-Bisabolol Inhibits Invasiveness and Motility in Pancreatic Cancer Through KISS1R Activation. First author PMID 26851012↗
  10. Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. First author DOI 10.1002/cam4.453↗
  11. [Borderline resectable pancreatic cancer - a definition and effective treatment strategy]. Co-author PMID 22421757↗
  12. Antitumor effects of α-bisabolol against pancreatic cancer. First author DOI 10.1111/j.1349-7006.2011.02082.x↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junpei Yamaguchi · 8 shared papers, 2015–2025 · strength 1.18
  2. Tomoki Ebata · 7 shared papers, 2012–2025 · strength 1.07
  3. Masaki Sunagawa · 6 shared papers, 2017–2025 · strength 1.04
  4. Yukihiro Yokoyama · 10 shared papers, 2011–2024 · strength 0.92
  5. Shunsuke Onoe · 4 shared papers, 2023–2025 · strength 0.76
  6. Taisuke Baba · 2 shared papers, 2023–2025 · strength 0.40
  7. Kimitoshi Yamazaki · 2 shared papers, 2023 · strength 0.31
  8. Masato Nagino · 2 shared papers, 2023 · strength 0.31
  9. Shoji Kawakatsu · 1 shared paper, 2025 · strength 0.25
  10. Motonobu Nishimura · 1 shared paper, 2025 · strength 0.25
  11. Masato Nagino · 3 shared papers, 2015–2017 · strength 0.21
  12. Tomohisa Otsu · 1 shared paper, 2025 · strength 0.20
  13. Masaya Suenaga · 1 shared paper, 2025 · strength 0.20
  14. Haruyoshi Tanaka · 1 shared paper, 2025 · strength 0.20
  15. Nobuhiko Nakagawa · 1 shared paper, 2025 · strength 0.20
  16. Mina Fukasawa · 1 shared paper, 2025 · strength 0.20
  17. Yasuhiro Kodera · 1 shared paper, 2025 · strength 0.20
  18. Tsutomu Fujii · 1 shared paper, 2025 · strength 0.20
  19. Mikiko Kano Takebayashi · 1 shared paper, 2023 · strength 0.15
  20. Takeshi Senga · 2 shared papers, 2016 · strength 0.14
  21. Tomohiro Miwa · 2 shared papers, 2015–2017 · strength 0.14
  22. Masato Nagino · 2 shared papers, 2012–2017 · strength 0.10
  23. Masanori Uno · 2 shared papers, 2011–2016 · strength 0.10
  24. Masato Nagino · 2 shared papers, 2011–2016 · strength 0.09
  25. Yoshihiko Murata · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.